BOJ keeps interest rates flat, but flags rate hikes on rising inflation, GDP
Investing.com - Jazz Pharma (NASDAQ: JAZZ) reported fourth quarter EPS of $6.60, $0.81 better than the analyst estimate of $5.79. Revenue for the quarter came in at $1.1B versus the consensus estimate of $1.06B.
Guidance
Jazz Pharma sees FY 2025 EPS of $22.50-$24.00 versus the analyst consensus of $22.03.
Jazz Pharma’s stock price closed at $139.67. It is up 14.87% in the last 3 months and up 5.20% in the last 12 months.
Jazz Pharma saw 5 positive EPS revisions and 5 negative EPS revisions in the last 90 days. See Jazz Pharma’s stock price’s past reactions to earnings here.
According to InvestingPro, Jazz Pharma’s Financial Health score is "great performance".
Check out Jazz Pharma’s recent earnings performance, and Jazz Pharma’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar